Mal-PEG2-NHS ester

Mal-PEG2-NHS ester is a heterobifunctional ADC linker widely employed in antibody-drug conjugate design. Featuring a maleimide group and an NHS ester, this linker enables selective conjugation between thiol-containing ADC cytotoxins and lysine residues on antibodies. The PEG2 spacer introduces hydrophilicity and flexibility, which facilitates optimal linker performance in ADC linker design by reducing steric hindrance and improving solubility, thereby enhancing the stability and pharmacokinetic profile of the resulting ADC.

In ADC payload applications, the maleimide functionality allows precise thiol-reactive conjugation, while the NHS ester reacts efficiently with primary amines on antibodies. This dual reactivity supports site-specific attachment and consistent drug-to-antibody ratios (DAR), critical parameters in developing ADCs with reproducible therapeutic efficacy. The PEG2 spacer also provides controlled distance between the antibody and cytotoxic payload, maintaining antibody-antigen binding capability and minimizing aggregation.

The chemical stability of Mal-PEG2-NHS ester under physiological conditions ensures that ADC payloads remain linked during circulation, allowing controlled delivery to target tumor cells. It is compatible with a variety of ADC cytotoxins, including microtubule inhibitors, DNA-damaging agents, and other potent payloads, supporting diverse oncology-focused bioconjugation strategies.

Mal-PEG2-NHS ester is commonly used in advanced ADC linker design, providing reliable conjugation chemistry, structural flexibility, and hydrophilicity. Its combination of precise reactivity and linker stability makes it a standard tool in constructing antibody-drug conjugates with consistent performance, enhanced solubility, and optimized therapeutic potential for targeted cancer therapy.